文献速递腹部介入CTMR

肝癌钇-90放射栓塞的CT与MRI进展

Advances in CT and MRI for Yttrium-90 Radioembolization of Hepatocellular Carcinoma.
PubMed 文献 · Acad Radiol · 2026-07-04

本文综述CT与MRI生物标志物在肝细胞癌钇-90放射栓塞中的应用进展,涵盖患者筛选、剂量规划、疗效评估与预后预测。增强标准优于单纯大小标准,LI-RADS TRA v2024引入放射特异性「非进展」分类,影像组学与身体成分指标显示预后价值但需标准化验证。

要点

  • 增强基础上的疗效标准优于单纯大小标准,适用于坏死性治疗评估
  • LI-RADS TRA v2024新增放射特异性「非进展」分类,可支持密切观察策略
  • 常规扫描可提取肌少症、脂肪组织密度等身体成分指标,独立关联预后

核心结论

  • 影像生物标志物的标准化与多中心验证是其转化为临床实践的必要条件

研究设计与样本

  • 叙述性综述,基于近期关于CT与MRI生物标志物预测TARE适用性、量化疗效及预测生存的证据

关键影像表现/征象

  • 动态增强MRI与锥形束CT结合灌注/碘图可近似微球分布,支持个体化剂量规划

诊断标准与关键数值

  • 疗效评估采用RECIST 1.1、改良RECIST及LI-RADS放射治疗反应算法
  • LI-RADS TRA v2024引入放射特异性指导及「非进展」分类
  • 增强基础上的标准在诱导坏死的治疗中优于单纯大小标准

临床应用与阅片要点

  • 治疗前预测肺分流分数、肿瘤与非肿瘤比值及功能性储备可用于TARE适用性筛选
  • LI-RADS TRA v2024的「非进展」分类在适当情况下可支持观察等待策略
  • 影像组学和机器学习对早期反应与总生存期预测显示良好准确性,但需标准化与前瞻性验证
  • 常规扫描提取的CT/MRI身体成分指标可作为实用的预后工具

局限性

  • 影像组学与机器学习方法需要标准化和前瞻性验证

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: Transarterial radioembolization (TARE) is increasingly used for patients with hepatocellular carcinoma (HCC) across Barcelona Clinic Liver Cancer stages. It provides local disease control and downstaging or bridging to definitive therapy in selected cases. Imaging plays a central role in patient selection, dosimetry planning, and post-treatment assessment. This review aims to summarize current advances on Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) biomarkers for optimizing TARE clinical management and prognostic evaluation.

MATERIALS AND METHODS: This narrative review was performed based on recent evidence regarding CT and MRI biomarkers used to predict TARE eligibility (eg, lung shunt fraction [LSF] prediction, tumour-to-non tumour ratio [TNR], functional reserve), quantify treatment response Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, modified RECIST, and Liver Imaging Reporting and Data System (LI-RADS) radiation Treatment Response Algorithm [TRA]), and predict survival (conventional features, body composition, radiomics).

RESULTS: Pre- and intraprocedural CT/MRI, including dynamic contrast-enhanced MRI and cone-beam CT (CBCT) with perfusion/iodine mapping, can approximate microsphere distribution and support personalized dosimetry. For response assessment, enhancement-based criteria outperform purely size-based metrics for therapies inducing necrosis. LI-RADS TRA v2024 introduces radiation-specific guidance and a "non-progressing" category that can underpin watch-and-wait strategies in appropriate contexts. Radiomics and machine learning show promising accuracy for predicting early response and overall survival (OS). However, they require standardization and prospective validation. CT/MRI-derived body composition metrics (eg, sarcopenia, adipose tissue density, fat-free muscle area) are independently associated with outcomes and are practical to extract from routine scans.

CONCLUSION: Standardization and multi-center validation are essential to translate these imaging biomarkers into clinical practice.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Liu, Pieterman, Dwarkasing, et al. Advances in CT and MRI for Yttrium-90 Radioembolization of Hepatocellular Carcinoma. Acad Radiol. 2026. PMID: 42401503. doi:10.1016/j.acra.2026.06.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。